Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

The Lancet HIV ◽

10.1016/s2352-3018(20)30241-1 ◽

2020 ◽

Vol 7 (10) ◽

pp. e666-e676 ◽

Author(s):

Willem D F Venter ◽

Simiso Sokhela ◽

Bryony Simmons ◽

Michelle Moorhouse ◽

Lee Fairlie ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Tenofovir Alafenamide ◽

Download Full-text

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

10.1016/s0140-6736(15)60616-x ◽

2015 ◽

Vol 385 (9987) ◽

pp. 2606-2615 ◽

Author(s):

Paul E Sax ◽

David Wohl ◽

Michael T Yin ◽

Frank Post ◽

Edwin DeJesus ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Download Full-text

Faculty Opinions recommendation of Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725442708.793509558 ◽

2015 ◽

Author(s):

Anthony Harries

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Download Full-text

Faculty Opinions recommendation of Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954439.793460355 ◽

2012 ◽

Author(s):

Kiat Ruxrungtham ◽

Wirach Maek-a-nantawat

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Download Full-text

Longer-Term Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide Versus Emtricitabine and Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Week 96 Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3772801 ◽

2021 ◽

Author(s):

Onyema Ogbuagu ◽

Peter J. Ruane ◽

Daniel Podzamczer ◽

Laura C. Salazar ◽

Keith Henry ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Tenofovir Alafenamide ◽

Exposure Prophylaxis ◽

Download Full-text

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

10.1016/s0140-6736(17)32340-1 ◽

2017 ◽

Vol 390 (10107) ◽

pp. 2073-2082 ◽

Author(s):

Paul E Sax ◽

Anton Pozniak ◽

M Luisa Montes ◽

Ellen Koenig ◽

Edwin DeJesus ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Download Full-text

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet HIV ◽

10.1016/s2352-3018(19)30077-3 ◽

2019 ◽

Vol 6 (6) ◽

pp. e355-e363 ◽

Author(s):

David A Wohl ◽

Yazdan Yazdanpanah ◽

Axel Baumgarten ◽

Amanda Clarke ◽

Melanie A Thompson ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Download Full-text

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(15)00348-5 ◽

2016 ◽

Vol 16 (1) ◽

pp. 43-52 ◽

Author(s):

Anthony Mills ◽

Jose R Arribas ◽

Jaime Andrade-Villanueva ◽

Giovanni DiPerri ◽

Jan Van Lunzen ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Phase 3 ◽

Open Label Phase ◽

Tenofovir Alafenamide ◽

Download Full-text

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

10.1016/s0140-6736(12)60918-0 ◽

2012 ◽

Vol 379 (9835) ◽

pp. 2429-2438 ◽

Author(s):

Edwin DeJesus ◽

Jürgen K Rockstroh ◽

Keith Henry ◽

Jean-Michel Molina ◽

Joseph Gathe ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Download Full-text

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet HIV ◽

10.1016/s2352-3018(21)00071-0 ◽

2021 ◽

Vol 8 (7) ◽

pp. e397-e407

Author(s):

Onyema Ogbuagu ◽

Peter J Ruane ◽

Daniel Podzamczer ◽

Laura C Salazar ◽

Keith Henry ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Tenofovir Alafenamide ◽

Exposure Prophylaxis ◽

Download Full-text

Using a single tablet regimen of darunavir, cobicistat, emcitrabine, and tenofovir alafenamide in virally suppressed HIV-1 patients is an adequate treatment option for controlling HIV

Clinical Research in Practice The Journal of Team Hippocrates ◽

10.22237/crp/1625097720 ◽

2021 ◽

Vol 7 (2) ◽

Author(s):

Priya Kathuria

Keyword(s):

Protease Inhibitors ◽

Treatment Option ◽

Tenofovir Disoproxil Fumarate ◽

Clinical Decision ◽

Efficacy And Safety ◽

Phase 3 ◽

Adequate Treatment ◽

Single Tablet Regimen ◽

Tenofovir Alafenamide ◽

A clinical decision report using: Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5(1):e23-e34. https://doi.org/10.1016/S2352-3018(17)30179-0 for a patient with viriologically suppressed HIV-1.

Download Full-text